Detalhe da pesquisa
1.
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Blood
; 143(19): 1931-1936, 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38364112
2.
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.
Blood
; 143(4): 336-341, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647641
3.
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML.
Blood
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691678
4.
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
N Engl J Med
; 386(1): 11-23, 2022 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34986284
5.
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Blood
; 142(20): 1697-1707, 2023 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37595359
6.
Overlapping features of therapy-related and de novo NPM1-mutated AML.
Blood
; 141(15): 1846-1857, 2023 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36508705
7.
A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
Br J Haematol
; 204(3): 871-876, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38016651
8.
Optimal Post-Remission Consolidation Therapy in Patients with AML.
Acta Haematol
; 147(2): 147-158, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38008085
9.
A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.
Br J Haematol
; 200(5): 573-578, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36413792
10.
Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.
Br J Haematol
; 196(6): 1344-1347, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34904225
11.
Therapy for isocitrate dehydrogenase 2 (IDH2)R172 -mutant acute myeloid leukaemia.
Br J Haematol
; 196(6): 1348-1352, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34870324
12.
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Br J Haematol
; 198(3): 528-534, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35388465
13.
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia.
Br J Haematol
; 196(6): 1337-1343, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34957541
14.
Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Blood
; 135(9): 680-688, 2020 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31932839
15.
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial.
Haematologica
; 107(7): 1518-1527, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34647442
16.
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial.
BMC Cancer
; 22(1): 1174, 2022 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36376888
17.
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
PLoS Med
; 18(1): e1003454, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33428632
18.
How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).
Br J Haematol
; 193(2): 231-244, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33058194
19.
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Br J Haematol
; 194(2): 298-308, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33961292
20.
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Br J Haematol
; 192(6): 1026-1030, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32458446